Pharmaceutical intermediates
Isavuconazonium sulfate Intermediates
4 pharmaceutical intermediates for Isavuconazonium sulfate. Indication: Aspergillus Infection; Cryptosporidium Infection; Fungal Infection; Mucorales Infection.
About Isavuconazonium sulfate
- Originator
- Basilea Pharmaceutica Ltd..
- Indication
- Aspergillus Infection; Cryptosporidium Infection; Fungal Infection; Mucorales Infection
- Approved Date
- 03/06/2015
- NCE Patent
- 09/06/2026
- DS/DP
- 10/31/2025
Available intermediates
4 intermediates currently listed for Isavuconazonium sulfate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (2R,3R)-3-(2,5-Difluorophenyl)-3-hydroxy-2-Methyl-4-(1H-1,2,4-triazol-1-yl)thiobutyraMide | 368421-58-3 | / | / |
| 1-(((2R,3S)-2-(2,5-difluorophenyl)-3-Methyloxiran-2-yl)Methyl)-1H-1,2,4-triazole | 241479-73-2 | / | / |
| 4-(2-Bromoacetyl)benzonitrile | 20099-89-2 | / | / |
| (2-(((1-Chloroethoxy)carbonyl)(methyl)amino)pyridin-3-yl)methyl 2-((tert-butoxycarbonyl)(methyl)amino)acetate | 338990-31-1 | / | / |
Building toward Isavuconazonium sulfate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →